- Home
- INNV vs BCAX Comparison
INNV vs BCAX Comparison
Compare INNV & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INNV
- BCAX
- Stock Information
- Founded
- INNV 2007
- BCAX 2018
- Country
- INNV United States
- BCAX United States
- Employees
- INNV N/A
- BCAX N/A
- Industry
- INNV Medical/Nursing Services
- BCAX
- Sector
- INNV Health Care
- BCAX
- Exchange
- INNV Nasdaq
- BCAX NYSE
- Market Cap
- INNV 571.1M
- BCAX 541.0M
- IPO Year
- INNV 2021
- BCAX 2024
- Fundamental
- Price
- INNV $3.84
- BCAX $11.75
- Analyst Decision
- INNV Sell
- BCAX Strong Buy
- Analyst Count
- INNV 2
- BCAX 7
- Target Price
- INNV $5.00
- BCAX $29.17
- AVG Volume (30 Days)
- INNV 50.2K
- BCAX 528.6K
- Earning Date
- INNV 09-09-2025
- BCAX 08-16-2025
- Dividend Yield
- INNV N/A
- BCAX N/A
- EPS Growth
- INNV N/A
- BCAX N/A
- EPS
- INNV N/A
- BCAX N/A
- Revenue
- INNV $831,683,000.00
- BCAX N/A
- Revenue This Year
- INNV $13.77
- BCAX N/A
- Revenue Next Year
- INNV $10.12
- BCAX N/A
- P/E Ratio
- INNV N/A
- BCAX N/A
- Revenue Growth
- INNV 12.19
- BCAX N/A
- 52 Week Low
- INNV $2.60
- BCAX $7.80
- 52 Week High
- INNV $6.69
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- INNV 45.57
- BCAX N/A
- Support Level
- INNV $3.71
- BCAX N/A
- Resistance Level
- INNV $4.09
- BCAX N/A
- Average True Range (ATR)
- INNV 0.29
- BCAX 0.00
- MACD
- INNV -0.05
- BCAX 0.00
- Stochastic Oscillator
- INNV 16.99
- BCAX 0.00
About INNV InnovAge Holding Corp.
InnovAge Holding Corp is a healthcare delivery platform by several participants focused on providing all-inclusive, capitated care to high-cost, dual-eligible seniors. Its patient-centered care delivery approach improves the quality of care while keeping them in their homes and reducing over-utilization of high-cost care settings such as hospitals and nursing homes. The company's segment includes PACE and others. It generates maximum revenue from the PACE segment.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.